Daiichi Sankyo and MorphoSys Expand Collaboration with Two New Cancer-Related Antibody Programs

Martinsried/Munich, Germany, May 18, 2009 - MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced today the start of a further two oncology-focused therapeutic antibody programs within its collaboration with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568, hereinafter Daiichi Sankyo). By exercising two options available under the parties' existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out pre-clinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies' existing agreement. Further financial details were not disclosed.

"The addition of these new oncology programs promises to strengthen still further our partnered antibody pipeline", commented Dr. Simon Moroney, CEO of MorphoSys. "We look forward to working with Daiichi Sankyo on the programs, and making progress towards our declared goal of establishing a broad therapeutic pipeline of HuCAL-based antibody drugs."

The two companies have been engaged in joint application of MorphoSys's advanced phage display and human antibody library technologies since March 2006. In March 2008, Daiichi Sankyo exercised its option to extend the contracting period until March 2011. Today, the collaboration encompasses four active therapeutic antibody programs. In May 2008, Daiichi Sankyo further strengthened its pipeline of novel targeted therapeutics in oncology by acquiring the German biotechnology company U3 Pharma AG. The cancer-related target molecules, which build the basis for the HuCAL-based programs, were part of U3 Pharma's portfolio.

About MorphoSys: MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R) and RapMAT(R) are registered trademarks of MorphoSys AG

About DAIICHI SANKYO DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly EUR 5.9 billion in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: www.daiichi-sankyo.eu.<http://www.daiichi-sankyo.eu>

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

For further information, please contact: Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100 allo@ala.comallo@ala.com> / neil@ala.comneil@ala.com>

Posted: May 2009


View comments

Hide
(web5)